Loading…
Loading…
United States University revenue increased 5% during Fiscal 2026, driven by solid organic lead generation Generated operating cash flow of $1.0 million in the fourth quarter, up from $0.6 million, enabling the resumption of marketing spend Gross margin expanded by 533 bps to 76% in the fourth quarter, lifting full year gross margin to 75% Fourth quarter net loss of $(4.3) million reflects two non-recurring non-cash charges totaling $3.2 million; Fiscal 2026 net loss was $(1.8) million Record fourth quarter Adjusted EBITDA of $3.3 million, up from $2.0 million; Fiscal 2026 Adjusted EBITDA reaches $10.6 million, a Company record, up from $5.7 million PHOENIX, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (OTCQB: ASPU) (“AGI” or the “Company”), an education technology holding company, today announced financial results for its fourth quarter of fiscal year 2026, ended April 30, 2026. Fourth Quarter Fiscal Year 2026 Summary Results Three Months Ended April 30, Years Ended April 30, $ in millions, except per share data 2026 2025 2026 2025 Revenue $ 10.3 $ 11.6 $ 43.3 $ 45.3 Gross Profit1 $ 7.8 $ 8.2 $ 32.5 $ 31.3 Gross Margin (%)1 76 % 71 % 75 % 69 % Net Income (Loss)2 $ (4.3 ) $ 0.6 $ (1.8 ) $ (1.5 ) Earnings (Loss) per Share - Basic $ (0.14 ) $ 0.02 $ (0.07 ) $ (0.07 ) Earnings (Loss) per Share - Diluted $ (0.14 ) $ 0.01 $ (0.07 ) $ (0.07 ) EBITDA3 $ (3.5 ) $ 1.7 $ 1.9 $ 2.9 Adjusted EBITDA3 $ 3.3 $ 2.0 $ 10.6 $ 5.7 _______________________ 1 GAAP gross profit calculation includes marketing, promotional and instructional costs, and amortization expense of $0.3 million and $0.4 million, and $1.5 million and $1.8 million, respectively for the three and twelve months ended April 30, 2026 and 2025, respectively.
Aspen Aerogels delivered sequential revenue and EBITDA improvement, with Q2 revenues topping guidance and Q3 outlook signaling further recovery. Thermal Barrier sales rebounded sequentially, especially in Europe, but remain pressured by regulatory shifts and evolving battery technologies. ASPN's EBITDA break-even threshold lowered to $175 million in annual revenue, reflecting cost discipline and operational progress despite fire-related disruptions.
Consider the kinds of endeavors that capture our interest. My theory: They often relate to things we can see, understand and admire in day to day life. This is probably why more children aspire to be actors than, say, accountants, and why investors gravitate more to AI or fancy tech, than say, materials science.
Aspen Aerogels NYSE: ASPN said it expects a sharp sequential increase in revenue and adjusted EBITDA in the third quarter, supported by energy-industrial project deliveries, rising General Motors EV production and expanding European demand for its PyroThin thermal barriers.
Q2 2026 Thermal Barrier revenue of $29.5 million, up 81% quarter-over-quarter Q3 2026 expected revenue range of $65 to $80 million and adjusted EBITDA range of $7 to $15 million European Thermal Barrier 2026 revenue outlook raised to $20 to $30 million PyroThin® award from Jaguar Land Rover for two next-generation vehicle architectures NORTHBOROUGH, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen” or the “Company”), a technology leader in sustainability and electrification solutions, today announced financial results for the second quarter of 2026, and discussed recent business developments.
NORTHBOROUGH, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen” or the “Company”), a technology leader in sustainability and electrification solutions, today announced that the Company is scheduled to present at the 29th Annual Oppenheimer Technology, Internet & Communications Conference, to be held virtually on Tuesday, August 11, 2026.
RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease. SOLANA BEACH, CA / ACCESS Newswire / July 31, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulated its partner Aspen Neuroscience, Inc. on receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for sasineprocel (ANPD001), Aspen's investigational autologous dopaminergic neuron cell replacement therapy for Parkinson's disease.
NORTHBOROUGH, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen” or the "Company") today announced that Don Young, President & Chief Executive Officer, and Grant Thoele, Chief Financial Officer & Treasurer, expect to discuss the Company's financial results for the second quarter ended June 30, 2026, during a conference call scheduled for Thursday, August 6, 2026, at 8:30 a.m. ET. The Company also expects to release its quarterly financial results before the market opens on Thursday, August 6, 2026.
No recent filings indexed.